ASH 2017 Annual Meeting Highlights in Hodgkin Lymphoma


Early Interim PET in Patients with Advanced-Stage HL Treated within the Phase 3 GHSG HD18 Study
Peter Borchmann, MD

Begin


Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Robert W. Chen, MD

Begin


Phase 2 Checkmate 205 Study Looking at Nivolumab for Newly Diagnosed Advanced-Stage cHL and Outcomes in Patients with Relapsed/Refractory cHL
Jonathon B. Cohen, MD, MS

Begin


Positive Phase 3 Data from ECHELON 1 Clinical Trial Comparing A+AVD as Frontline Therapy in Previously Untreated Advanced HL
Joseph M. Connors, MD, FRCPC

Begin


Studies That Will Impact or Shape Treatment of HL in 2018
Matthew Matasar, MD

Begin

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2018 MediCom Worldwide, Inc. All rights reserved